# Wave Life Sciences, Inc.: financial statements, quarterly

WVE · Nasdaq · CIK 1631574 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wve.md) · [Financials](/companies/wve/financials.md) · [Filings](/companies/wve/filings.md) · [Insiders](/companies/wve/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wve/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [29.1 d](/filings/0001193125-26-073472.md) | [12.5](/filings/0000950170-25-066404.md) | [19.7](/filings/0000950170-25-099884.md) | not reported | not reported | [9.2](/filings/0001193125-26-183587.md) | [8.7](/filings/0001193125-26-324949.md) | [7.6](/filings/0001193125-26-432714.md) | [17.2 d](/filings/0001193125-26-073472.md) | [38.2](/filings/0001193125-26-183587.md) | [2.3](/filings/0001193125-26-324949.md) | [13.2](/filings/0001193125-26-432714.md) |
| Research and development | $m | [34.1 d](/filings/0001193125-26-073472.md) | [33.4](/filings/0000950170-25-066404.md) | [40.4](/filings/0000950170-25-099884.md) | [41.2](/filings/0001193125-25-273288.md) | [44.6 d](/filings/0001193125-26-073472.md) | [40.6](/filings/0001193125-26-183587.md) | [43.5](/filings/0001193125-26-324949.md) | [45.9](/filings/0001193125-26-432714.md) | [52.8 d](/filings/0001193125-26-073472.md) | [47.4](/filings/0001193125-26-183587.md) | [51.3](/filings/0001193125-26-324949.md) | [53.8](/filings/0001193125-26-432714.md) |
| Operating income | $m | [(18.7) d](/filings/0001193125-26-073472.md) | [(34.5)](/filings/0000950170-25-066404.md) | [(35.0)](/filings/0000950170-25-099884.md) | [(63.9)](/filings/0001193125-25-273288.md) | [23.0 d](/filings/0001193125-26-073472.md) | [(49.8)](/filings/0001193125-26-183587.md) | [(52.8)](/filings/0001193125-26-324949.md) | [(56.4)](/filings/0001193125-26-432714.md) | [(56.5) d](/filings/0001193125-26-073472.md) | [(31.3)](/filings/0001193125-26-183587.md) | [(73.8)](/filings/0001193125-26-324949.md) | [(66.0)](/filings/0001193125-26-432714.md) |
| Income tax | $m | [0.0 d](/filings/0001193125-26-073472.md) | [0.0](/filings/0000950170-25-066404.md) | [0.0](/filings/0000950170-25-099884.md) | [0.0](/filings/0001193125-25-273288.md) | [0.0 d](/filings/0001193125-26-073472.md) | [0.0](/filings/0001193125-26-183587.md) | [0.0](/filings/0001193125-26-324949.md) | [0.0](/filings/0001193125-26-432714.md) | [0.0 d](/filings/0001193125-26-073472.md) | [0.0](/filings/0001193125-26-183587.md) | [0.0](/filings/0001193125-26-324949.md) | [0.0](/filings/0001193125-26-432714.md) |
| Net income | $m | [(16.3) d](/filings/0001193125-26-073472.md) | [(31.6)](/filings/0001193125-25-273288.md) | [(32.9)](/filings/0001193125-25-273288.md) | [(61.8)](/filings/0001193125-25-273288.md) | [29.3 d](/filings/0001193125-26-073472.md) | [(46.9)](/filings/0001193125-26-432714.md) | [(50.5)](/filings/0001193125-26-432714.md) | [(53.9)](/filings/0001193125-26-432714.md) | [(53.2) d](/filings/0001193125-26-073472.md) | [(26.1)](/filings/0001193125-26-432714.md) | [(69.4)](/filings/0001193125-26-432714.md) | [(61.9)](/filings/0001193125-26-432714.md) |
| Diluted EPS | $ per share | not reported | [(0.24)](/filings/0000950170-25-066404.md) | [(0.25)](/filings/0000950170-25-099884.md) | [(0.47)](/filings/0001193125-25-273288.md) | not reported | [(0.29)](/filings/0001193125-26-183587.md) | [(0.31)](/filings/0001193125-26-324949.md) | [(0.32)](/filings/0001193125-26-432714.md) | not reported | [(0.13)](/filings/0001193125-26-183587.md) | [(0.34)](/filings/0001193125-26-324949.md) | [(0.30)](/filings/0001193125-26-432714.md) |
| Basic EPS | $ per share | not reported | [(0.24)](/filings/0000950170-25-066404.md) | [(0.25)](/filings/0000950170-25-099884.md) | [(0.47)](/filings/0001193125-25-273288.md) | not reported | [(0.29)](/filings/0001193125-26-183587.md) | [(0.31)](/filings/0001193125-26-324949.md) | [(0.32)](/filings/0001193125-26-432714.md) | not reported | [(0.13)](/filings/0001193125-26-183587.md) | [(0.34)](/filings/0001193125-26-324949.md) | [(0.30)](/filings/0001193125-26-432714.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [200](/filings/0000950170-25-031322.md) | [181](/filings/0000950170-24-057457.md) | [154](/filings/0000950170-24-093341.md) | [311](/filings/0000950170-24-124595.md) | [302](/filings/0001193125-26-073472.md) | [243](/filings/0000950170-25-066404.md) | [208](/filings/0000950170-25-099884.md) | [196](/filings/0001193125-25-273288.md) | [602](/filings/0001193125-26-432714.md) | [545](/filings/0001193125-26-183587.md) | [368](/filings/0001193125-26-324949.md) | [197](/filings/0001193125-26-432714.md) |
| Current assets | $m | [235](/filings/0000950170-25-031322.md) | [197](/filings/0000950170-24-057457.md) | [172](/filings/0000950170-24-093341.md) | [325](/filings/0000950170-24-124595.md) | [320](/filings/0001193125-26-073472.md) | [258](/filings/0000950170-25-066404.md) | [224](/filings/0000950170-25-099884.md) | [215](/filings/0001193125-25-273288.md) | [615](/filings/0001193125-26-432714.md) | [561](/filings/0001193125-26-183587.md) | [508](/filings/0001193125-26-324949.md) | [459](/filings/0001193125-26-432714.md) |
| Total assets | $m | [275](/filings/0000950170-25-031322.md) | [235](/filings/0000950170-24-057457.md) | [209](/filings/0000950170-24-093341.md) | [359](/filings/0000950170-24-124595.md) | [352](/filings/0001193125-26-073472.md) | [288](/filings/0000950170-25-066404.md) | [252](/filings/0000950170-25-099884.md) | [241](/filings/0001193125-25-273288.md) | [638](/filings/0001193125-26-432714.md) | [584](/filings/0001193125-26-183587.md) | [558](/filings/0001193125-26-324949.md) | [508](/filings/0001193125-26-432714.md) |
| Current liabilities | $m | [186](/filings/0000950170-25-031322.md) | [166](/filings/0000950170-24-057457.md) | [173](/filings/0000950170-24-093341.md) | [171](/filings/0000950170-24-124595.md) | [111](/filings/0001193125-26-073472.md) | [87.4](/filings/0000950170-25-066404.md) | [87.4](/filings/0000950170-25-099884.md) | [85.9](/filings/0001193125-25-273288.md) | [95.1](/filings/0001193125-26-432714.md) | [49.8](/filings/0001193125-26-183587.md) | [50.8](/filings/0001193125-26-324949.md) | [54.8](/filings/0001193125-26-432714.md) |
| Total liabilities | $m | [227](/filings/0000950170-25-031322.md) | [202](/filings/0000950170-24-057457.md) | [204](/filings/0000950170-24-093341.md) | [209](/filings/0000950170-24-124595.md) | [135](/filings/0001193125-26-073472.md) | [109](/filings/0000950170-25-066404.md) | [105](/filings/0000950170-25-099884.md) | [109](/filings/0001193125-25-273288.md) | [112](/filings/0001193125-26-432714.md) | [71.8](/filings/0001193125-26-183587.md) | [105](/filings/0001193125-26-324949.md) | [106](/filings/0001193125-26-432714.md) |
| Shareholders' equity | $m | [39.6](/filings/0001193125-26-073472.md) | [25.4](/filings/0001193125-25-273288.md) | [(3.5)](/filings/0001193125-25-273288.md) | [142](/filings/0001193125-25-273288.md) | [210](/filings/0001193125-26-432714.md) | [172](/filings/0001193125-26-432714.md) | [139](/filings/0001193125-26-432714.md) | [125](/filings/0001193125-26-432714.md) | [518](/filings/0001193125-26-432714.md) | [512](/filings/0001193125-26-432714.md) | [454](/filings/0001193125-26-432714.md) | [402](/filings/0001193125-26-432714.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(33.2) d](/filings/0001193125-26-073472.md) | [(33.4)](/filings/0000950170-25-066404.md) | [(27.5) d](/filings/0000950170-25-099884.md) | [(46.5) d](/filings/0001193125-25-273288.md) | [(43.6) d](/filings/0001193125-26-073472.md) | [(63.0)](/filings/0001193125-26-183587.md) | [(46.0) d](/filings/0001193125-26-324949.md) | [(44.7) d](/filings/0001193125-26-432714.md) | [(33.8) d](/filings/0001193125-26-073472.md) | [(59.6)](/filings/0001193125-26-183587.md) | [(53.6) d](/filings/0001193125-26-324949.md) | [(60.1) d](/filings/0001193125-26-432714.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001193125-26-073472.md) | [0.4](/filings/0000950170-25-066404.md) | [0.1 d](/filings/0000950170-25-099884.md) | [0.4 d](/filings/0001193125-25-273288.md) | [0.1 d](/filings/0001193125-26-073472.md) | [0.2](/filings/0001193125-26-183587.md) | [0.3 d](/filings/0001193125-26-324949.md) | [0.2 d](/filings/0001193125-26-432714.md) | [(0.0) d](/filings/0001193125-26-073472.md) | [0.4](/filings/0001193125-26-183587.md) | [0.9 d](/filings/0001193125-26-324949.md) | [0.0 d](/filings/0001193125-26-432714.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [102](/filings/0000950170-24-057457.md) | [105](/filings/0000950170-24-093341.md) | [107](/filings/0000950170-24-124595.md) | [129](/filings/0000950170-25-066404.md) | [130](/filings/0000950170-25-099884.md) | [133](/filings/0001193125-25-273288.md) | [163](/filings/0001193125-26-183587.md) | [164](/filings/0001193125-26-324949.md) | [168](/filings/0001193125-26-432714.md) | [200](/filings/0001193125-26-183587.md) | [204](/filings/0001193125-26-324949.md) | [204](/filings/0001193125-26-432714.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 197,228,968 at 2026-10-21, from the cover of the [10-Q filed 2026-10-27](/filings/0001193125-26-432714.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 27, 2026, 15:22 ET. No prices; not investment advice.